Alnylam Pharmaceuticals | ALNY - Sales Revenues

Stock Price
335.42
Daily Change
4.18 1.26%
Monthly
-17.47%
Yearly
20.55%
Q1 Forecast
327.65

Alnylam Pharmaceuticals reported $1.25B in Sales Revenues for its fiscal quarter ending in September of 2025.





Sales Change Date
Acadia Pharmaceuticals USD 278.6M 14M Sep/2025
Agios Pharmaceuticals USD 12.9M 450K Sep/2025
Alnylam Pharmaceuticals USD 1.25B 476.31M Sep/2025
Amgen USD 9.9B 340M Dec/2025
Arrowhead Research USD 264.03M 7.56M Dec/2025
BioMarin Pharmaceutical USD 776M 49M Sep/2025
Incyte USD 1.37B 310M Sep/2025
Ionis Pharmaceuticals USD 157M 295M Sep/2025
Moderna USD 1.02B 878M Sep/2025
Neurocrine Biosciences USD 794.9M 107.4M Sep/2025
Novartis USD 14.36B 478M Sep/2025
PTC Therapeutics USD 211M 32.1M Sep/2025
Regeneron Pharmaceuticals USD 3.88B 130M Dec/2025
Sanofi EUR 12.2B 3.19B Dec/2025
Sarepta Therapeutics USD 399.4M 211.69M Sep/2025
Takeda JPY 1.19T 80B Dec/2025
Tectonic Therapeutic USD 0 0 Dec/2024
Ultragenyx Pharmaceutical USD 160M 6.5M Sep/2025
Vertex Pharmaceuticals USD 3.08B 120M Sep/2025
Xencor USD 21M 22.61M Sep/2025